Prescription-Event Monitoring

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 203-216

  Shakir, Saad A W ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

Automated signal generation; Long latency adverse reactions; Nested case control studies; Pharmacogenetics in medicinal efficacy and safety; Postmarketing surveillance (PMS) studies; Prescription event monitoring (PEM); Risk management and pharmacovigilance; Signal detection and pharmacovigilance evaluation

Indexed keywords

EID: 84889411524     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch12     Document Type: Chapter

References (32)

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961;2:1358.
2. Committee on Safety of Drugs. Cited in: Mann RD, ed., Modern Drug Use-An Enquiry on Historical Principles. Lancaster, PA: MTP Press-Kluwer, 1984; p. 619.
3. Rawlins MD, Jefferys DB. Study of United Kingdom product licence applications containing new active substances, 1987-9. BMJ 1991;302:223-5.
4. Rawlins MD, Mann RD. Monitoring adverse events and reactions. In: Mann RD, Rawlins MD, RM Auty, eds, A Textbook of Pharmaceutical Medicine, Current Practice. Carnforth: Parthenon, 1993; p. 319.
5. Finney DJ. The design and logic of a monitor of drug use. J Chron Dis 1965;18:77-98.
6. Inman WHW, Weber JCP. Post-marketing surveillance in the general population. In: Inman WHW, Gill EP, eds, Monitoring for Drug Safety, 2nd edn. Lancaster: MTP, 1985; p. 13.
7. Committee on Safety of Medicines. Cited in: Mann RD, ed., Adverse Drug Reactions. Carnforth: Parthenon, 1987; pp. 62-3.
8. Beardon PHG, Brown SV, McGilchrist MM, McKendick AD, McDevitt DG, MacDonald TM. Primary non-compliance with prescribed medication in primary care. BMJ 1993;307:846-8.
9. Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol Drug Saf 1999;8:179-89.
10. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrhythmias associated with cisapride: limitations of the pharmacoepidemiological studies conducted and proposals for the future. Pharmacoepidemiol Drug Saf 2003;12:31-40.
11. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected adverse drug reactions to newly marketed ("black triangle") drugs in general practice: observational study. Br Med J 1998;317:119-20.
12. Heeley E, Riley J, Layton D, Wilton LV, Shakir S. Prescriptionevent monitoring and reporting of adverse drug reactions. Lancet 2001;356:1872-3.
13. Layton D, Hughes K, Harris S, Shakir SAW. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003:42;1332-41.
14. Wilton LV, Heeley EL, Pickering RM, Shakir SAW. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychpharmacol 2001;15:120-6.
15. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "nonsedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-6.
16. Layton D, Clark D, Pearce G, Shakir SAW. Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England. Eur J Clin Pharmacol 2001;57:167-76.
17. Shakir S, Wilton LV, Heeley E, Layton D. Cardiovascular events in users of sildenafil: results from first phase of prescription-event monitoring in England. BMJ 2001;322:651-2.
18. Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000. Eur J Clin Pharmacol 2003;59:767-73.
19. Wilton L, Pearce G, Edet E, Freemantle S, Stephens MDB, Mann RD. The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14 772 patients. Br J Urol 1996;78:379-84.
20. Wilton LV, Stephens MDB, Mann RD. Visual field defect associated with vigabatrin: observational cohort study. BMJ 1999;319:1165-66.
21. Biswas PN, Wilton LV, Shakir SAW. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13,554 patients in England. J Psychopharmacol 2003;17;121-6.
22. Biswas PN, Wilton LV, Pearce GL, Freemantle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol 2001;15;265-71.
23. Layton D, Shakir SAW. Safety profile of rofecoxib as used in general practice in England: results of a prescription-event monitoring study. Br J Clin Pharmacol 2003;55:166-74.
24. Wilton LV, Key C, Shakir SAW. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11,541 patients in England. Drug Saf. 2003:26;121-32.
25. Heeley E, Wilton LV, Shakir SA. Automated signal generation in prescription-event monitoring. Drug Saf 2002;25:423-32.
26. Layton D, Heeley E, Shakir SAW. Identification and evaluation of a possible signal of exacerbation of colitis during rofecoxib treatment, using Prescription-Event Monitoring (PEM) data. J Clin Pharm Ther 2004;29:171-81.
27. Stephens MDB, Wilton LV, Pearce G, Mann RD. Visual field defects in patients taking vigabatrin. Pharmacoepidemiol Drug Saf 1997;6 (Suppl 2): S18.
28. Wilton LV, Stephens MDB, Mann RD. Visual field defects in patients on long term vigabatrin therapy. Pharmacoepidemiol Drug Saf 1999;8 (suppl 2): 5108.
29. Wilton LV, Pearce GL, Martin RM, Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol 1998;105:882-9.
30. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-6.
31. Martin RM, Shakir S. Age- and gender-specific asthma death rates in patients taking long-acting beta2-agonists: prescription event monitoring pharmacosurveillance studies. Drug Saf 2001;24:475-81.
32. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998;46:505-30.